Activating KRAS gene point mutations have been detected in many types of human tumours [72]. Such oncogenic forms of the KRAS gene are prevalent in pancreatic carcinomas (>80%), colon carcinomas (40–50%), and lung carcinomas (30–50%), but are also present in biliary tract malignancies, endometrial cancer, cervical cancer, bladder cancer, liver cancer, myeloid leukemia [73, 74] and breast cancer [75].

http://www.sciencedaily.com/releases/2011/11/111114095721.htm

More Anna Grażyna Gasecka's questions See All
Similar questions and discussions